nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.327	1	CiPCiCtD
Pazopanib—kidney cancer—melanoma	0.237	1	CtDrD
Pazopanib—MAP3K9—melanoma	0.112	0.454	CbGaD
Pazopanib—FGF1—melanoma	0.0415	0.168	CbGaD
Pazopanib—FLT1—melanoma	0.0296	0.12	CbGaD
Pazopanib—PDGFRA—melanoma	0.0238	0.0965	CbGaD
Pazopanib—KDR—melanoma	0.0185	0.075	CbGaD
Pazopanib—KIT—melanoma	0.0175	0.0708	CbGaD
Pazopanib—ABCG2—Vemurafenib—melanoma	0.0147	0.215	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—melanoma	0.00977	0.143	CbGbCtD
Pazopanib—CYP1A2—Carmustine—melanoma	0.00767	0.112	CbGbCtD
Pazopanib—CYP1A2—Vemurafenib—melanoma	0.00606	0.0888	CbGbCtD
Pazopanib—CYP3A4—Temozolomide—melanoma	0.0058	0.0849	CbGbCtD
Pazopanib—ABCG2—Docetaxel—melanoma	0.00504	0.0739	CbGbCtD
Pazopanib—CYP2D6—Vemurafenib—melanoma	0.00499	0.0731	CbGbCtD
Pazopanib—CYP1A2—Dacarbazine—melanoma	0.00465	0.068	CbGbCtD
Pazopanib—ABCB1—melanoma	0.00403	0.0163	CbGaD
Pazopanib—ABCB1—Dactinomycin—melanoma	0.00352	0.0516	CbGbCtD
Pazopanib—CYP3A4—Vemurafenib—melanoma	0.00318	0.0465	CbGbCtD
Pazopanib—ABCB1—Docetaxel—melanoma	0.00182	0.0266	CbGbCtD
Pazopanib—FGF1—dermis—melanoma	0.00121	0.0463	CbGeAlD
Pazopanib—CYP3A4—Docetaxel—melanoma	0.00109	0.016	CbGbCtD
Pazopanib—FGFR3—appendage—melanoma	0.000883	0.0338	CbGeAlD
Pazopanib—FGFR3—skin epidermis—melanoma	0.000734	0.0281	CbGeAlD
Pazopanib—FLT1—umbilical vein—melanoma	0.000682	0.0261	CbGeAlD
Pazopanib—FGF1—appendage—melanoma	0.000612	0.0234	CbGeAlD
Pazopanib—KDR—umbilical vein—melanoma	0.000577	0.022	CbGeAlD
Pazopanib—KDR—hindlimb—melanoma	0.000528	0.0202	CbGeAlD
Pazopanib—FGFR3—hair follicle—melanoma	0.000524	0.02	CbGeAlD
Pazopanib—FGF1—skin epidermis—melanoma	0.000509	0.0195	CbGeAlD
Pazopanib—FGFR2—skin epidermis—melanoma	0.000481	0.0184	CbGeAlD
Pazopanib—LIMK2—hair follicle—melanoma	0.000455	0.0174	CbGeAlD
Pazopanib—KDR—appendage—melanoma	0.000453	0.0173	CbGeAlD
Pazopanib—FLT4—endothelium—melanoma	0.000416	0.0159	CbGeAlD
Pazopanib—FLT4—blood vessel—melanoma	0.000384	0.0147	CbGeAlD
Pazopanib—FGF1—endothelium—melanoma	0.000369	0.0141	CbGeAlD
Pazopanib—MAP3K9—mammalian vulva—melanoma	0.000351	0.0134	CbGeAlD
Pazopanib—FGF1—blood vessel—melanoma	0.000341	0.013	CbGeAlD
Pazopanib—KIT—skin epidermis—melanoma	0.000334	0.0128	CbGeAlD
Pazopanib—TAOK1—eye—melanoma	0.000332	0.0127	CbGeAlD
Pazopanib—FLT1—endothelium—melanoma	0.000323	0.0124	CbGeAlD
Pazopanib—SH2B3—eye—melanoma	0.000312	0.0119	CbGeAlD
Pazopanib—SH2B3—retina—melanoma	0.00031	0.0118	CbGeAlD
Pazopanib—FLT1—blood vessel—melanoma	0.000298	0.0114	CbGeAlD
Pazopanib—ITK—mammalian vulva—melanoma	0.000289	0.0111	CbGeAlD
Pazopanib—KDR—endothelium—melanoma	0.000273	0.0105	CbGeAlD
Pazopanib—TAOK1—mammalian vulva—melanoma	0.000263	0.0101	CbGeAlD
Pazopanib—KDR—blood vessel—melanoma	0.000252	0.00964	CbGeAlD
Pazopanib—MAP3K9—head—melanoma	0.000251	0.00959	CbGeAlD
Pazopanib—SH2B3—mammalian vulva—melanoma	0.000248	0.00948	CbGeAlD
Pazopanib—FGF1—neck—melanoma	0.000244	0.00932	CbGeAlD
Pazopanib—KIT—endothelium—melanoma	0.000242	0.00926	CbGeAlD
Pazopanib—FGFR2—neck—melanoma	0.00023	0.0088	CbGeAlD
Pazopanib—FGFR3—skin of body—melanoma	0.000228	0.0087	CbGeAlD
Pazopanib—KIT—blood vessel—melanoma	0.000223	0.00854	CbGeAlD
Pazopanib—PDGFRB—blood vessel—melanoma	0.000218	0.00834	CbGeAlD
Pazopanib—FLT1—neck—melanoma	0.000213	0.00816	CbGeAlD
Pazopanib—RIOK2—mammalian vulva—melanoma	0.000208	0.00793	CbGeAlD
Pazopanib—FGFR3—mammalian vulva—melanoma	0.000208	0.00793	CbGeAlD
Pazopanib—FLT4—eye—melanoma	0.000204	0.0078	CbGeAlD
Pazopanib—PIP4K2C—retina—melanoma	0.000201	0.00769	CbGeAlD
Pazopanib—TAOK1—head—melanoma	0.000188	0.0072	CbGeAlD
Pazopanib—STK36—mammalian vulva—melanoma	0.000186	0.00713	CbGeAlD
Pazopanib—PI4KB—mammalian vulva—melanoma	0.000184	0.00702	CbGeAlD
Pazopanib—FGF1—eye—melanoma	0.000181	0.00693	CbGeAlD
Pazopanib—KDR—neck—melanoma	0.00018	0.00689	CbGeAlD
Pazopanib—LIMK2—mammalian vulva—melanoma	0.00018	0.00689	CbGeAlD
Pazopanib—FGF1—retina—melanoma	0.00018	0.00687	CbGeAlD
Pazopanib—SH2B3—head—melanoma	0.000177	0.00678	CbGeAlD
Pazopanib—MAP3K9—lymph node—melanoma	0.000176	0.00672	CbGeAlD
Pazopanib—AURKC—head—melanoma	0.000175	0.00668	CbGeAlD
Pazopanib—FGFR2—eye—melanoma	0.000171	0.00655	CbGeAlD
Pazopanib—PIP4K2C—mammalian vulva—melanoma	0.000161	0.00616	CbGeAlD
Pazopanib—KIT—neck—melanoma	0.00016	0.00611	CbGeAlD
Pazopanib—FGFR1—mammalian vulva—melanoma	0.00016	0.00611	CbGeAlD
Pazopanib—FLT1—eye—melanoma	0.000159	0.00607	CbGeAlD
Pazopanib—FGF1—skin of body—melanoma	0.000158	0.00603	CbGeAlD
Pazopanib—FLT1—retina—melanoma	0.000157	0.00601	CbGeAlD
Pazopanib—PDGFRB—neck—melanoma	0.000156	0.00597	CbGeAlD
Pazopanib—STK16—head—melanoma	0.000151	0.00577	CbGeAlD
Pazopanib—TAOK3—eye—melanoma	0.00015	0.00572	CbGeAlD
Pazopanib—LYN—head—melanoma	0.000149	0.00571	CbGeAlD
Pazopanib—FGFR2—skin of body—melanoma	0.000149	0.00569	CbGeAlD
Pazopanib—FGFR3—head—melanoma	0.000148	0.00568	CbGeAlD
Pazopanib—RIOK2—head—melanoma	0.000148	0.00568	CbGeAlD
Pazopanib—TAOK3—retina—melanoma	0.000148	0.00567	CbGeAlD
Pazopanib—MAP3K19—head—melanoma	0.000147	0.00562	CbGeAlD
Pazopanib—BMPR1B—head—melanoma	0.000147	0.00562	CbGeAlD
Pazopanib—ITK—lymph node—melanoma	0.000145	0.00554	CbGeAlD
Pazopanib—LCK—mammalian vulva—melanoma	0.000143	0.00547	CbGeAlD
Pazopanib—EPHB6—skin of body—melanoma	0.000136	0.00522	CbGeAlD
Pazopanib—KDR—eye—melanoma	0.000134	0.00513	CbGeAlD
Pazopanib—STK36—head—melanoma	0.000133	0.0051	CbGeAlD
Pazopanib—KDR—retina—melanoma	0.000133	0.00508	CbGeAlD
Pazopanib—TAOK1—lymph node—melanoma	0.000132	0.00504	CbGeAlD
Pazopanib—PI4KB—head—melanoma	0.000131	0.00502	CbGeAlD
Pazopanib—CSF1R—eye—melanoma	0.000131	0.00501	CbGeAlD
Pazopanib—LIMK2—head—melanoma	0.000129	0.00493	CbGeAlD
Pazopanib—FLT1—mammalian vulva—melanoma	0.000126	0.00481	CbGeAlD
Pazopanib—EPHB6—mammalian vulva—melanoma	0.000124	0.00476	CbGeAlD
Pazopanib—SH2B3—lymph node—melanoma	0.000124	0.00475	CbGeAlD
Pazopanib—AURKC—lymph node—melanoma	0.000122	0.00467	CbGeAlD
Pazopanib—STK10—mammalian vulva—melanoma	0.000119	0.00456	CbGeAlD
Pazopanib—TAOK3—mammalian vulva—melanoma	0.000119	0.00454	CbGeAlD
Pazopanib—PDGFRB—eye—melanoma	0.000116	0.00444	CbGeAlD
Pazopanib—FLT4—head—melanoma	0.000116	0.00443	CbGeAlD
Pazopanib—PIP4K2C—head—melanoma	0.000115	0.00441	CbGeAlD
Pazopanib—CSF1R—skin of body—melanoma	0.000114	0.00435	CbGeAlD
Pazopanib—PLK4—lymph node—melanoma	0.000112	0.00428	CbGeAlD
Pazopanib—MAP3K2—head—melanoma	0.000109	0.00418	CbGeAlD
Pazopanib—KDR—mammalian vulva—melanoma	0.000106	0.00407	CbGeAlD
Pazopanib—MAP2K5—mammalian vulva—melanoma	0.000106	0.00407	CbGeAlD
Pazopanib—STK16—lymph node—melanoma	0.000106	0.00404	CbGeAlD
Pazopanib—RIOK2—lymph node—melanoma	0.000104	0.00397	CbGeAlD
Pazopanib—CSF1R—mammalian vulva—melanoma	0.000104	0.00397	CbGeAlD
Pazopanib—KIT—skin of body—melanoma	0.000103	0.00395	CbGeAlD
Pazopanib—BMPR1B—lymph node—melanoma	0.000103	0.00393	CbGeAlD
Pazopanib—FGF1—head—melanoma	0.000103	0.00393	CbGeAlD
Pazopanib—Rilpivirine—ABCB1—melanoma	0.000102	1	CrCbGaD
Pazopanib—PDGFRB—skin of body—melanoma	0.000101	0.00386	CbGeAlD
Pazopanib—FGFR2—head—melanoma	9.72e-05	0.00372	CbGeAlD
Pazopanib—KIT—mammalian vulva—melanoma	9.43e-05	0.00361	CbGeAlD
Pazopanib—STK36—lymph node—melanoma	9.34e-05	0.00357	CbGeAlD
Pazopanib—PDGFRB—mammalian vulva—melanoma	9.21e-05	0.00352	CbGeAlD
Pazopanib—PI4KB—lymph node—melanoma	9.2e-05	0.00352	CbGeAlD
Pazopanib—LIMK2—lymph node—melanoma	9.03e-05	0.00345	CbGeAlD
Pazopanib—FLT1—head—melanoma	9.01e-05	0.00344	CbGeAlD
Pazopanib—EPHB6—head—melanoma	8.9e-05	0.0034	CbGeAlD
Pazopanib—STK10—head—melanoma	8.53e-05	0.00326	CbGeAlD
Pazopanib—TAOK3—head—melanoma	8.49e-05	0.00325	CbGeAlD
Pazopanib—PDGFRA—head—melanoma	8.44e-05	0.00323	CbGeAlD
Pazopanib—FLT4—lymph node—melanoma	8.11e-05	0.0031	CbGeAlD
Pazopanib—PIP4K2C—lymph node—melanoma	8.07e-05	0.00308	CbGeAlD
Pazopanib—FGFR1—lymph node—melanoma	8e-05	0.00306	CbGeAlD
Pazopanib—MAP3K2—lymph node—melanoma	7.65e-05	0.00292	CbGeAlD
Pazopanib—KDR—head—melanoma	7.62e-05	0.00291	CbGeAlD
Pazopanib—MAP2K5—head—melanoma	7.62e-05	0.00291	CbGeAlD
Pazopanib—Neutropenia—Carmustine—melanoma	7.56e-05	0.00243	CcSEcCtD
Pazopanib—Decreased appetite—Vemurafenib—melanoma	7.56e-05	0.00243	CcSEcCtD
Pazopanib—Stomatitis—Dactinomycin—melanoma	7.51e-05	0.00241	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Vemurafenib—melanoma	7.5e-05	0.00241	CcSEcCtD
Pazopanib—Fatigue—Vemurafenib—melanoma	7.49e-05	0.00241	CcSEcCtD
Pazopanib—Haemoglobin—Bleomycin—melanoma	7.45e-05	0.0024	CcSEcCtD
Pazopanib—CSF1R—head—melanoma	7.43e-05	0.00284	CbGeAlD
Pazopanib—Haemorrhage—Bleomycin—melanoma	7.41e-05	0.00238	CcSEcCtD
Pazopanib—Hypoaesthesia—Bleomycin—melanoma	7.38e-05	0.00237	CcSEcCtD
Pazopanib—Neutropenia—Temozolomide—melanoma	7.3e-05	0.00235	CcSEcCtD
Pazopanib—FGF1—lymph node—melanoma	7.21e-05	0.00276	CbGeAlD
Pazopanib—LCK—lymph node—melanoma	7.16e-05	0.00274	CbGeAlD
Pazopanib—Photosensitivity reaction—Temozolomide—melanoma	7.13e-05	0.00229	CcSEcCtD
Pazopanib—Weight decreased—Temozolomide—melanoma	7.07e-05	0.00227	CcSEcCtD
Pazopanib—Stomatitis—Carmustine—melanoma	7.03e-05	0.00226	CcSEcCtD
Pazopanib—Infestation—Temozolomide—melanoma	6.97e-05	0.00224	CcSEcCtD
Pazopanib—Infestation NOS—Temozolomide—melanoma	6.97e-05	0.00224	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Docetaxel—melanoma	6.91e-05	0.00222	CcSEcCtD
Pazopanib—Flushing—Bleomycin—melanoma	6.88e-05	0.00221	CcSEcCtD
Pazopanib—Stomatitis—Temozolomide—melanoma	6.79e-05	0.00218	CcSEcCtD
Pazopanib—KIT—head—melanoma	6.75e-05	0.00258	CbGeAlD
Pazopanib—Hepatic failure—Docetaxel—melanoma	6.69e-05	0.00215	CcSEcCtD
Pazopanib—Chills—Bleomycin—melanoma	6.65e-05	0.00214	CcSEcCtD
Pazopanib—Cardiac failure congestive—Docetaxel—melanoma	6.63e-05	0.00213	CcSEcCtD
Pazopanib—PDGFRB—head—melanoma	6.59e-05	0.00252	CbGeAlD
Pazopanib—Hepatobiliary disease—Temozolomide—melanoma	6.59e-05	0.00212	CcSEcCtD
Pazopanib—Alopecia—Bleomycin—melanoma	6.55e-05	0.00211	CcSEcCtD
Pazopanib—Haemoglobin—Carmustine—melanoma	6.5e-05	0.00209	CcSEcCtD
Pazopanib—Haemorrhage—Carmustine—melanoma	6.47e-05	0.00208	CcSEcCtD
Pazopanib—Erythema—Bleomycin—melanoma	6.45e-05	0.00208	CcSEcCtD
Pazopanib—Hypoaesthesia—Carmustine—melanoma	6.44e-05	0.00207	CcSEcCtD
Pazopanib—Hot flush—Docetaxel—melanoma	6.43e-05	0.00207	CcSEcCtD
Pazopanib—Flushing—Dactinomycin—melanoma	6.42e-05	0.00206	CcSEcCtD
Pazopanib—Oedema peripheral—Carmustine—melanoma	6.37e-05	0.00205	CcSEcCtD
Pazopanib—Menopausal symptoms—Docetaxel—melanoma	6.37e-05	0.00205	CcSEcCtD
Pazopanib—Connective tissue disorder—Carmustine—melanoma	6.36e-05	0.00205	CcSEcCtD
Pazopanib—FLT1—lymph node—melanoma	6.31e-05	0.00241	CbGeAlD
Pazopanib—Haemoglobin—Temozolomide—melanoma	6.28e-05	0.00202	CcSEcCtD
Pazopanib—Haemorrhage—Temozolomide—melanoma	6.25e-05	0.00201	CcSEcCtD
Pazopanib—Asthenia—Vemurafenib—melanoma	6.24e-05	0.00201	CcSEcCtD
Pazopanib—EPHB6—lymph node—melanoma	6.24e-05	0.00238	CbGeAlD
Pazopanib—Hypoaesthesia—Temozolomide—melanoma	6.22e-05	0.002	CcSEcCtD
Pazopanib—Chills—Dactinomycin—melanoma	6.2e-05	0.002	CcSEcCtD
Pazopanib—Urinary tract disorder—Temozolomide—melanoma	6.17e-05	0.00199	CcSEcCtD
Pazopanib—Oedema peripheral—Temozolomide—melanoma	6.16e-05	0.00198	CcSEcCtD
Pazopanib—Cardiac failure—Docetaxel—melanoma	6.16e-05	0.00198	CcSEcCtD
Pazopanib—Pruritus—Vemurafenib—melanoma	6.15e-05	0.00198	CcSEcCtD
Pazopanib—Connective tissue disorder—Temozolomide—melanoma	6.14e-05	0.00198	CcSEcCtD
Pazopanib—Lethargy—Docetaxel—melanoma	6.13e-05	0.00197	CcSEcCtD
Pazopanib—Urethral disorder—Temozolomide—melanoma	6.13e-05	0.00197	CcSEcCtD
Pazopanib—Alopecia—Dactinomycin—melanoma	6.11e-05	0.00197	CcSEcCtD
Pazopanib—ABCB1—blood vessel—melanoma	6.05e-05	0.00231	CbGeAlD
Pazopanib—Eye disorder—Carmustine—melanoma	6.05e-05	0.00195	CcSEcCtD
Pazopanib—Hyponatraemia—Docetaxel—melanoma	6.03e-05	0.00194	CcSEcCtD
Pazopanib—Erythema—Dactinomycin—melanoma	6.02e-05	0.00194	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Docetaxel—melanoma	6.01e-05	0.00193	CcSEcCtD
Pazopanib—Flushing—Carmustine—melanoma	6e-05	0.00193	CcSEcCtD
Pazopanib—STK10—lymph node—melanoma	5.97e-05	0.00228	CbGeAlD
Pazopanib—Anaemia—Bleomycin—melanoma	5.96e-05	0.00192	CcSEcCtD
Pazopanib—TAOK3—lymph node—melanoma	5.95e-05	0.00227	CbGeAlD
Pazopanib—Diarrhoea—Vemurafenib—melanoma	5.95e-05	0.00191	CcSEcCtD
Pazopanib—PDGFRA—lymph node—melanoma	5.91e-05	0.00226	CbGeAlD
Pazopanib—Eye disorder—Temozolomide—melanoma	5.84e-05	0.00188	CcSEcCtD
Pazopanib—Flushing—Temozolomide—melanoma	5.8e-05	0.00187	CcSEcCtD
Pazopanib—Cardiac disorder—Temozolomide—melanoma	5.8e-05	0.00187	CcSEcCtD
Pazopanib—Leukopenia—Bleomycin—melanoma	5.78e-05	0.00186	CcSEcCtD
Pazopanib—Dizziness—Vemurafenib—melanoma	5.75e-05	0.00185	CcSEcCtD
Pazopanib—Alopecia—Carmustine—melanoma	5.72e-05	0.00184	CcSEcCtD
Pazopanib—Angiopathy—Temozolomide—melanoma	5.67e-05	0.00182	CcSEcCtD
Pazopanib—Mental disorder—Carmustine—melanoma	5.67e-05	0.00182	CcSEcCtD
Pazopanib—Mediastinal disorder—Temozolomide—melanoma	5.64e-05	0.00181	CcSEcCtD
Pazopanib—Malnutrition—Carmustine—melanoma	5.63e-05	0.00181	CcSEcCtD
Pazopanib—Erythema—Carmustine—melanoma	5.63e-05	0.00181	CcSEcCtD
Pazopanib—Cough—Bleomycin—melanoma	5.63e-05	0.00181	CcSEcCtD
Pazopanib—Chills—Temozolomide—melanoma	5.61e-05	0.0018	CcSEcCtD
Pazopanib—Dehydration—Docetaxel—melanoma	5.59e-05	0.0018	CcSEcCtD
Pazopanib—Anaemia—Dactinomycin—melanoma	5.56e-05	0.00179	CcSEcCtD
Pazopanib—Liver function test abnormal—Docetaxel—melanoma	5.55e-05	0.00179	CcSEcCtD
Pazopanib—Vomiting—Vemurafenib—melanoma	5.53e-05	0.00178	CcSEcCtD
Pazopanib—Alopecia—Temozolomide—melanoma	5.53e-05	0.00178	CcSEcCtD
Pazopanib—Dry skin—Docetaxel—melanoma	5.51e-05	0.00177	CcSEcCtD
Pazopanib—Myalgia—Bleomycin—melanoma	5.49e-05	0.00177	CcSEcCtD
Pazopanib—Chest pain—Bleomycin—melanoma	5.49e-05	0.00177	CcSEcCtD
Pazopanib—Abdominal pain upper—Docetaxel—melanoma	5.49e-05	0.00177	CcSEcCtD
Pazopanib—Rash—Vemurafenib—melanoma	5.48e-05	0.00176	CcSEcCtD
Pazopanib—Mental disorder—Temozolomide—melanoma	5.48e-05	0.00176	CcSEcCtD
Pazopanib—Dermatitis—Vemurafenib—melanoma	5.48e-05	0.00176	CcSEcCtD
Pazopanib—Headache—Vemurafenib—melanoma	5.45e-05	0.00175	CcSEcCtD
Pazopanib—Malnutrition—Temozolomide—melanoma	5.44e-05	0.00175	CcSEcCtD
Pazopanib—Erythema—Temozolomide—melanoma	5.44e-05	0.00175	CcSEcCtD
Pazopanib—Breast disorder—Docetaxel—melanoma	5.43e-05	0.00175	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Docetaxel—melanoma	5.41e-05	0.00174	CcSEcCtD
Pazopanib—Leukopenia—Dactinomycin—melanoma	5.39e-05	0.00173	CcSEcCtD
Pazopanib—Nasopharyngitis—Docetaxel—melanoma	5.37e-05	0.00173	CcSEcCtD
Pazopanib—KDR—lymph node—melanoma	5.33e-05	0.00204	CbGeAlD
Pazopanib—MAP2K5—lymph node—melanoma	5.33e-05	0.00204	CbGeAlD
Pazopanib—Dysgeusia—Temozolomide—melanoma	5.33e-05	0.00171	CcSEcCtD
Pazopanib—Vision blurred—Carmustine—melanoma	5.31e-05	0.00171	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Docetaxel—melanoma	5.3e-05	0.00171	CcSEcCtD
Pazopanib—Oedema—Bleomycin—melanoma	5.27e-05	0.00169	CcSEcCtD
Pazopanib—Infection—Bleomycin—melanoma	5.23e-05	0.00168	CcSEcCtD
Pazopanib—Anaemia—Carmustine—melanoma	5.21e-05	0.00167	CcSEcCtD
Pazopanib—CSF1R—lymph node—melanoma	5.2e-05	0.00199	CbGeAlD
Pazopanib—ABCG2—mammalian vulva—melanoma	5.18e-05	0.00198	CbGeAlD
Pazopanib—Nausea—Vemurafenib—melanoma	5.16e-05	0.00166	CcSEcCtD
Pazopanib—Thrombocytopenia—Bleomycin—melanoma	5.16e-05	0.00166	CcSEcCtD
Pazopanib—Vision blurred—Temozolomide—melanoma	5.13e-05	0.00165	CcSEcCtD
Pazopanib—Myalgia—Dactinomycin—melanoma	5.12e-05	0.00165	CcSEcCtD
Pazopanib—Leukopenia—Carmustine—melanoma	5.04e-05	0.00162	CcSEcCtD
Pazopanib—Anaemia—Temozolomide—melanoma	5.03e-05	0.00162	CcSEcCtD
Pazopanib—Anorexia—Bleomycin—melanoma	5.02e-05	0.00161	CcSEcCtD
Pazopanib—Oedema—Dactinomycin—melanoma	4.91e-05	0.00158	CcSEcCtD
Pazopanib—Infection—Dactinomycin—melanoma	4.88e-05	0.00157	CcSEcCtD
Pazopanib—Leukopenia—Temozolomide—melanoma	4.87e-05	0.00157	CcSEcCtD
Pazopanib—Hypertension—Carmustine—melanoma	4.86e-05	0.00156	CcSEcCtD
Pazopanib—Neutropenia—Docetaxel—melanoma	4.86e-05	0.00156	CcSEcCtD
Pazopanib—Thrombocytopenia—Dactinomycin—melanoma	4.81e-05	0.00155	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Bleomycin—melanoma	4.8e-05	0.00154	CcSEcCtD
Pazopanib—Chest pain—Carmustine—melanoma	4.8e-05	0.00154	CcSEcCtD
Pazopanib—Myalgia—Carmustine—melanoma	4.8e-05	0.00154	CcSEcCtD
Pazopanib—Cough—Temozolomide—melanoma	4.75e-05	0.00153	CcSEcCtD
Pazopanib—Paraesthesia—Bleomycin—melanoma	4.73e-05	0.00152	CcSEcCtD
Pazopanib—KIT—lymph node—melanoma	4.73e-05	0.00181	CbGeAlD
Pazopanib—Weight decreased—Docetaxel—melanoma	4.7e-05	0.00151	CcSEcCtD
Pazopanib—Hypertension—Temozolomide—melanoma	4.7e-05	0.00151	CcSEcCtD
Pazopanib—Dyspnoea—Bleomycin—melanoma	4.7e-05	0.00151	CcSEcCtD
Pazopanib—Anorexia—Dactinomycin—melanoma	4.68e-05	0.00151	CcSEcCtD
Pazopanib—Myalgia—Temozolomide—melanoma	4.63e-05	0.00149	CcSEcCtD
Pazopanib—Arthralgia—Temozolomide—melanoma	4.63e-05	0.00149	CcSEcCtD
Pazopanib—Infestation—Docetaxel—melanoma	4.63e-05	0.00149	CcSEcCtD
Pazopanib—Infestation NOS—Docetaxel—melanoma	4.63e-05	0.00149	CcSEcCtD
Pazopanib—PDGFRB—lymph node—melanoma	4.62e-05	0.00176	CbGeAlD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	4.6e-05	0.00148	CcSEcCtD
Pazopanib—Oedema—Carmustine—melanoma	4.6e-05	0.00148	CcSEcCtD
Pazopanib—Decreased appetite—Bleomycin—melanoma	4.58e-05	0.00147	CcSEcCtD
Pazopanib—Infection—Carmustine—melanoma	4.57e-05	0.00147	CcSEcCtD
Pazopanib—Acute coronary syndrome—Docetaxel—melanoma	4.57e-05	0.00147	CcSEcCtD
Pazopanib—Myocardial infarction—Docetaxel—melanoma	4.54e-05	0.00146	CcSEcCtD
Pazopanib—Dry mouth—Temozolomide—melanoma	4.53e-05	0.00146	CcSEcCtD
Pazopanib—Jaundice—Docetaxel—melanoma	4.52e-05	0.00145	CcSEcCtD
Pazopanib—Stomatitis—Docetaxel—melanoma	4.52e-05	0.00145	CcSEcCtD
Pazopanib—Pain—Bleomycin—melanoma	4.5e-05	0.00145	CcSEcCtD
Pazopanib—Thrombocytopenia—Carmustine—melanoma	4.5e-05	0.00145	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Dactinomycin—melanoma	4.47e-05	0.00144	CcSEcCtD
Pazopanib—Oedema—Temozolomide—melanoma	4.44e-05	0.00143	CcSEcCtD
Pazopanib—Infection—Temozolomide—melanoma	4.41e-05	0.00142	CcSEcCtD
Pazopanib—Anorexia—Carmustine—melanoma	4.38e-05	0.00141	CcSEcCtD
Pazopanib—Hepatobiliary disease—Docetaxel—melanoma	4.38e-05	0.00141	CcSEcCtD
Pazopanib—Epistaxis—Docetaxel—melanoma	4.37e-05	0.00141	CcSEcCtD
Pazopanib—Nervous system disorder—Temozolomide—melanoma	4.36e-05	0.0014	CcSEcCtD
Pazopanib—Thrombocytopenia—Temozolomide—melanoma	4.35e-05	0.0014	CcSEcCtD
Pazopanib—Skin disorder—Temozolomide—melanoma	4.31e-05	0.00139	CcSEcCtD
Pazopanib—Hyperhidrosis—Temozolomide—melanoma	4.29e-05	0.00138	CcSEcCtD
Pazopanib—Decreased appetite—Dactinomycin—melanoma	4.27e-05	0.00137	CcSEcCtD
Pazopanib—Fatigue—Dactinomycin—melanoma	4.23e-05	0.00136	CcSEcCtD
Pazopanib—Anorexia—Temozolomide—melanoma	4.23e-05	0.00136	CcSEcCtD
Pazopanib—Pain—Dactinomycin—melanoma	4.2e-05	0.00135	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Carmustine—melanoma	4.19e-05	0.00135	CcSEcCtD
Pazopanib—Haemoglobin—Docetaxel—melanoma	4.18e-05	0.00134	CcSEcCtD
Pazopanib—Haemorrhage—Docetaxel—melanoma	4.16e-05	0.00134	CcSEcCtD
Pazopanib—Insomnia—Carmustine—melanoma	4.16e-05	0.00134	CcSEcCtD
Pazopanib—Hypoaesthesia—Docetaxel—melanoma	4.14e-05	0.00133	CcSEcCtD
Pazopanib—Paraesthesia—Carmustine—melanoma	4.13e-05	0.00133	CcSEcCtD
Pazopanib—Urinary tract disorder—Docetaxel—melanoma	4.11e-05	0.00132	CcSEcCtD
Pazopanib—Dyspnoea—Carmustine—melanoma	4.1e-05	0.00132	CcSEcCtD
Pazopanib—Oedema peripheral—Docetaxel—melanoma	4.1e-05	0.00132	CcSEcCtD
Pazopanib—Somnolence—Carmustine—melanoma	4.09e-05	0.00131	CcSEcCtD
Pazopanib—Connective tissue disorder—Docetaxel—melanoma	4.09e-05	0.00131	CcSEcCtD
Pazopanib—Urethral disorder—Docetaxel—melanoma	4.08e-05	0.00131	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Temozolomide—melanoma	4.05e-05	0.0013	CcSEcCtD
Pazopanib—Insomnia—Temozolomide—melanoma	4.02e-05	0.00129	CcSEcCtD
Pazopanib—Gastrointestinal pain—Dactinomycin—melanoma	4.02e-05	0.00129	CcSEcCtD
Pazopanib—Decreased appetite—Carmustine—melanoma	4e-05	0.00129	CcSEcCtD
Pazopanib—Paraesthesia—Temozolomide—melanoma	3.99e-05	0.00128	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Carmustine—melanoma	3.97e-05	0.00128	CcSEcCtD
Pazopanib—Dyspnoea—Temozolomide—melanoma	3.96e-05	0.00127	CcSEcCtD
Pazopanib—Somnolence—Temozolomide—melanoma	3.95e-05	0.00127	CcSEcCtD
Pazopanib—Pain—Carmustine—melanoma	3.93e-05	0.00126	CcSEcCtD
Pazopanib—Dyspepsia—Temozolomide—melanoma	3.91e-05	0.00126	CcSEcCtD
Pazopanib—Eye disorder—Docetaxel—melanoma	3.89e-05	0.00125	CcSEcCtD
Pazopanib—Abdominal pain—Dactinomycin—melanoma	3.88e-05	0.00125	CcSEcCtD
Pazopanib—Decreased appetite—Temozolomide—melanoma	3.86e-05	0.00124	CcSEcCtD
Pazopanib—Cardiac disorder—Docetaxel—melanoma	3.86e-05	0.00124	CcSEcCtD
Pazopanib—Flushing—Docetaxel—melanoma	3.86e-05	0.00124	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Temozolomide—melanoma	3.84e-05	0.00123	CcSEcCtD
Pazopanib—Fatigue—Temozolomide—melanoma	3.83e-05	0.00123	CcSEcCtD
Pazopanib—Pain—Temozolomide—melanoma	3.8e-05	0.00122	CcSEcCtD
Pazopanib—Asthenia—Bleomycin—melanoma	3.78e-05	0.00122	CcSEcCtD
Pazopanib—Angiopathy—Docetaxel—melanoma	3.77e-05	0.00121	CcSEcCtD
Pazopanib—Gastrointestinal pain—Carmustine—melanoma	3.76e-05	0.00121	CcSEcCtD
Pazopanib—Mediastinal disorder—Docetaxel—melanoma	3.75e-05	0.00121	CcSEcCtD
Pazopanib—Chills—Docetaxel—melanoma	3.73e-05	0.0012	CcSEcCtD
Pazopanib—Pruritus—Bleomycin—melanoma	3.73e-05	0.0012	CcSEcCtD
Pazopanib—Alopecia—Docetaxel—melanoma	3.67e-05	0.00118	CcSEcCtD
Pazopanib—Mental disorder—Docetaxel—melanoma	3.64e-05	0.00117	CcSEcCtD
Pazopanib—Abdominal pain—Carmustine—melanoma	3.63e-05	0.00117	CcSEcCtD
Pazopanib—Gastrointestinal pain—Temozolomide—melanoma	3.63e-05	0.00117	CcSEcCtD
Pazopanib—Malnutrition—Docetaxel—melanoma	3.62e-05	0.00116	CcSEcCtD
Pazopanib—Erythema—Docetaxel—melanoma	3.62e-05	0.00116	CcSEcCtD
Pazopanib—Dysgeusia—Docetaxel—melanoma	3.54e-05	0.00114	CcSEcCtD
Pazopanib—Asthenia—Dactinomycin—melanoma	3.52e-05	0.00113	CcSEcCtD
Pazopanib—Abdominal pain—Temozolomide—melanoma	3.51e-05	0.00113	CcSEcCtD
Pazopanib—Muscle spasms—Docetaxel—melanoma	3.48e-05	0.00112	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—melanoma	3.36e-05	0.00108	CcSEcCtD
Pazopanib—Vomiting—Bleomycin—melanoma	3.35e-05	0.00108	CcSEcCtD
Pazopanib—Anaemia—Docetaxel—melanoma	3.35e-05	0.00108	CcSEcCtD
Pazopanib—Rash—Bleomycin—melanoma	3.32e-05	0.00107	CcSEcCtD
Pazopanib—Dermatitis—Bleomycin—melanoma	3.32e-05	0.00107	CcSEcCtD
Pazopanib—Asthenia—Carmustine—melanoma	3.3e-05	0.00106	CcSEcCtD
Pazopanib—Syncope—Docetaxel—melanoma	3.25e-05	0.00104	CcSEcCtD
Pazopanib—Leukopenia—Docetaxel—melanoma	3.24e-05	0.00104	CcSEcCtD
Pazopanib—ABCB1—retina—melanoma	3.19e-05	0.00122	CbGeAlD
Pazopanib—Asthenia—Temozolomide—melanoma	3.19e-05	0.00103	CcSEcCtD
Pazopanib—Loss of consciousness—Docetaxel—melanoma	3.18e-05	0.00102	CcSEcCtD
Pazopanib—Cough—Docetaxel—melanoma	3.16e-05	0.00102	CcSEcCtD
Pazopanib—Diarrhoea—Carmustine—melanoma	3.15e-05	0.00101	CcSEcCtD
Pazopanib—Pruritus—Temozolomide—melanoma	3.14e-05	0.00101	CcSEcCtD
Pazopanib—Nausea—Bleomycin—melanoma	3.13e-05	0.00101	CcSEcCtD
Pazopanib—Hypertension—Docetaxel—melanoma	3.13e-05	0.00101	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—melanoma	3.12e-05	0.001	CcSEcCtD
Pazopanib—Rash—Dactinomycin—melanoma	3.1e-05	0.000996	CcSEcCtD
Pazopanib—Myalgia—Docetaxel—melanoma	3.08e-05	0.000991	CcSEcCtD
Pazopanib—Arthralgia—Docetaxel—melanoma	3.08e-05	0.000991	CcSEcCtD
Pazopanib—Chest pain—Docetaxel—melanoma	3.08e-05	0.000991	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	3.06e-05	0.000985	CcSEcCtD
Pazopanib—Dizziness—Carmustine—melanoma	3.04e-05	0.000978	CcSEcCtD
Pazopanib—Diarrhoea—Temozolomide—melanoma	3.04e-05	0.000978	CcSEcCtD
Pazopanib—Dry mouth—Docetaxel—melanoma	3.01e-05	0.00097	CcSEcCtD
Pazopanib—Oedema—Docetaxel—melanoma	2.95e-05	0.00095	CcSEcCtD
Pazopanib—Dizziness—Temozolomide—melanoma	2.94e-05	0.000945	CcSEcCtD
Pazopanib—Infection—Docetaxel—melanoma	2.93e-05	0.000944	CcSEcCtD
Pazopanib—Vomiting—Carmustine—melanoma	2.92e-05	0.00094	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—melanoma	2.92e-05	0.000938	CcSEcCtD
Pazopanib—Shock—Docetaxel—melanoma	2.91e-05	0.000935	CcSEcCtD
Pazopanib—Rash—Carmustine—melanoma	2.9e-05	0.000932	CcSEcCtD
Pazopanib—Nervous system disorder—Docetaxel—melanoma	2.9e-05	0.000932	CcSEcCtD
Pazopanib—Dermatitis—Carmustine—melanoma	2.9e-05	0.000932	CcSEcCtD
Pazopanib—Thrombocytopenia—Docetaxel—melanoma	2.89e-05	0.00093	CcSEcCtD
Pazopanib—Headache—Carmustine—melanoma	2.88e-05	0.000926	CcSEcCtD
Pazopanib—Skin disorder—Docetaxel—melanoma	2.87e-05	0.000923	CcSEcCtD
Pazopanib—Vomiting—Temozolomide—melanoma	2.82e-05	0.000909	CcSEcCtD
Pazopanib—Anorexia—Docetaxel—melanoma	2.82e-05	0.000906	CcSEcCtD
Pazopanib—Rash—Temozolomide—melanoma	2.8e-05	0.000901	CcSEcCtD
Pazopanib—Dermatitis—Temozolomide—melanoma	2.8e-05	0.0009	CcSEcCtD
Pazopanib—Headache—Temozolomide—melanoma	2.78e-05	0.000895	CcSEcCtD
Pazopanib—Nausea—Carmustine—melanoma	2.73e-05	0.000878	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Docetaxel—melanoma	2.69e-05	0.000866	CcSEcCtD
Pazopanib—Insomnia—Docetaxel—melanoma	2.67e-05	0.00086	CcSEcCtD
Pazopanib—Paraesthesia—Docetaxel—melanoma	2.65e-05	0.000853	CcSEcCtD
Pazopanib—Nausea—Temozolomide—melanoma	2.64e-05	0.000849	CcSEcCtD
Pazopanib—Dyspnoea—Docetaxel—melanoma	2.63e-05	0.000847	CcSEcCtD
Pazopanib—Somnolence—Docetaxel—melanoma	2.63e-05	0.000845	CcSEcCtD
Pazopanib—Dyspepsia—Docetaxel—melanoma	2.6e-05	0.000837	CcSEcCtD
Pazopanib—ABCG2—lymph node—melanoma	2.59e-05	0.000992	CbGeAlD
Pazopanib—Decreased appetite—Docetaxel—melanoma	2.57e-05	0.000826	CcSEcCtD
Pazopanib—ABCB1—mammalian vulva—melanoma	2.55e-05	0.000976	CbGeAlD
Pazopanib—Gastrointestinal disorder—Docetaxel—melanoma	2.55e-05	0.00082	CcSEcCtD
Pazopanib—Fatigue—Docetaxel—melanoma	2.55e-05	0.000819	CcSEcCtD
Pazopanib—CYP2D6—head—melanoma	2.54e-05	0.000971	CbGeAlD
Pazopanib—Pain—Docetaxel—melanoma	2.53e-05	0.000813	CcSEcCtD
Pazopanib—Gastrointestinal pain—Docetaxel—melanoma	2.42e-05	0.000777	CcSEcCtD
Pazopanib—Abdominal pain—Docetaxel—melanoma	2.34e-05	0.000751	CcSEcCtD
Pazopanib—Asthenia—Docetaxel—melanoma	2.12e-05	0.000682	CcSEcCtD
Pazopanib—Pruritus—Docetaxel—melanoma	2.09e-05	0.000672	CcSEcCtD
Pazopanib—Diarrhoea—Docetaxel—melanoma	2.02e-05	0.00065	CcSEcCtD
Pazopanib—Dizziness—Docetaxel—melanoma	1.95e-05	0.000628	CcSEcCtD
Pazopanib—Vomiting—Docetaxel—melanoma	1.88e-05	0.000604	CcSEcCtD
Pazopanib—Rash—Docetaxel—melanoma	1.86e-05	0.000599	CcSEcCtD
Pazopanib—Dermatitis—Docetaxel—melanoma	1.86e-05	0.000599	CcSEcCtD
Pazopanib—Headache—Docetaxel—melanoma	1.85e-05	0.000595	CcSEcCtD
Pazopanib—ABCB1—head—melanoma	1.83e-05	0.000698	CbGeAlD
Pazopanib—Nausea—Docetaxel—melanoma	1.75e-05	0.000564	CcSEcCtD
Pazopanib—ABCB1—lymph node—melanoma	1.28e-05	0.000489	CbGeAlD
Pazopanib—LYN—Signaling Pathways—CDKN1B—melanoma	2.52e-07	3.95e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—melanoma	2.52e-07	3.95e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK3—melanoma	2.52e-07	3.94e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—melanoma	2.51e-07	3.94e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—melanoma	2.51e-07	3.94e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STAT3—melanoma	2.49e-07	3.9e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NRAS—melanoma	2.48e-07	3.89e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—IL6—melanoma	2.48e-07	3.89e-06	CbGpPWpGaD
Pazopanib—KIT—Immune System—AKT1—melanoma	2.48e-07	3.89e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.47e-07	3.88e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CASP3—melanoma	2.47e-07	3.88e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—melanoma	2.47e-07	3.87e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HRAS—melanoma	2.46e-07	3.86e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—melanoma	2.46e-07	3.85e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HRAS—melanoma	2.45e-07	3.85e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.45e-07	3.84e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—melanoma	2.45e-07	3.84e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—melanoma	2.43e-07	3.82e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—STAT3—melanoma	2.43e-07	3.81e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—NRAS—melanoma	2.43e-07	3.8e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1B1—melanoma	2.42e-07	3.8e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK3—melanoma	2.42e-07	3.79e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FGF2—melanoma	2.42e-07	3.79e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—melanoma	2.41e-07	3.79e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—melanoma	2.41e-07	3.77e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—HRAS—melanoma	2.4e-07	3.77e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HRAS—melanoma	2.39e-07	3.75e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK1—melanoma	2.39e-07	3.75e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—melanoma	2.39e-07	3.75e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—melanoma	2.39e-07	3.75e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP9—melanoma	2.39e-07	3.74e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—melanoma	2.38e-07	3.74e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—melanoma	2.38e-07	3.74e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—melanoma	2.38e-07	3.73e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—melanoma	2.38e-07	3.73e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—melanoma	2.38e-07	3.73e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK3—melanoma	2.38e-07	3.73e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—AKT1—melanoma	2.37e-07	3.72e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—melanoma	2.37e-07	3.72e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STAT3—melanoma	2.36e-07	3.7e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NFKB1—melanoma	2.36e-07	3.7e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NRAS—melanoma	2.36e-07	3.69e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—IL6—melanoma	2.35e-07	3.69e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STAT3—melanoma	2.35e-07	3.69e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—melanoma	2.35e-07	3.69e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—melanoma	2.35e-07	3.69e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—AKT1—melanoma	2.35e-07	3.69e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NRAS—melanoma	2.35e-07	3.68e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—IL6—melanoma	2.35e-07	3.68e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—AKT1—melanoma	2.35e-07	3.68e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—HRAS—melanoma	2.34e-07	3.68e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—HRAS—melanoma	2.34e-07	3.67e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP9—melanoma	2.34e-07	3.66e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—melanoma	2.34e-07	3.66e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—AKT1—melanoma	2.33e-07	3.65e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—melanoma	2.33e-07	3.65e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK3—melanoma	2.32e-07	3.64e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—melanoma	2.32e-07	3.64e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—melanoma	2.31e-07	3.62e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NFKB1—melanoma	2.31e-07	3.62e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK1—melanoma	2.3e-07	3.61e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—melanoma	2.3e-07	3.61e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—IL6—melanoma	2.3e-07	3.61e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PRKCA—melanoma	2.3e-07	3.6e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL6—melanoma	2.29e-07	3.59e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—AKT1—melanoma	2.29e-07	3.59e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ERCC2—melanoma	2.28e-07	3.57e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MDM2—melanoma	2.26e-07	3.55e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK1—melanoma	2.26e-07	3.55e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—melanoma	2.26e-07	3.54e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—melanoma	2.26e-07	3.54e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—melanoma	2.26e-07	3.54e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK3—melanoma	2.26e-07	3.54e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK3—melanoma	2.25e-07	3.53e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL6—melanoma	2.24e-07	3.52e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—IL6—melanoma	2.24e-07	3.51e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—HRAS—melanoma	2.23e-07	3.5e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—melanoma	2.23e-07	3.5e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP17A1—melanoma	2.22e-07	3.48e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HRAS—melanoma	2.21e-07	3.47e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK1—melanoma	2.21e-07	3.46e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—melanoma	2.21e-07	3.46e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—melanoma	2.21e-07	3.46e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CB—melanoma	2.2e-07	3.45e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—melanoma	2.19e-07	3.44e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—melanoma	2.19e-07	3.43e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—melanoma	2.17e-07	3.41e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—AKT1—melanoma	2.17e-07	3.41e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.17e-07	3.4e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—AKT1—melanoma	2.17e-07	3.4e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PRKCA—melanoma	2.17e-07	3.4e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ERCC2—melanoma	2.15e-07	3.37e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK1—melanoma	2.15e-07	3.36e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—melanoma	2.15e-07	3.36e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—melanoma	2.14e-07	3.36e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK1—melanoma	2.14e-07	3.36e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—melanoma	2.14e-07	3.36e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—IL6—melanoma	2.14e-07	3.35e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.14e-07	3.35e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—melanoma	2.14e-07	3.35e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—AKT1—melanoma	2.12e-07	3.33e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STAT3—melanoma	2.12e-07	3.33e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CXCL8—melanoma	2.12e-07	3.32e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NRAS—melanoma	2.12e-07	3.32e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—IL6—melanoma	2.12e-07	3.32e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—AKT1—melanoma	2.11e-07	3.32e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—melanoma	2.1e-07	3.29e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNA11—melanoma	2.1e-07	3.29e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—melanoma	2.09e-07	3.27e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—melanoma	2.08e-07	3.26e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STAT3—melanoma	2.08e-07	3.26e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NRAS—melanoma	2.07e-07	3.25e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—AKT1—melanoma	2.07e-07	3.25e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—AKT1—melanoma	2.07e-07	3.24e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1B—melanoma	2.07e-07	3.24e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CG—melanoma	2.07e-07	3.24e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—FASN—melanoma	2.05e-07	3.22e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—melanoma	2.03e-07	3.18e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK3—melanoma	2.03e-07	3.18e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CASP3—melanoma	2.03e-07	3.18e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—melanoma	2.02e-07	3.17e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—melanoma	2.02e-07	3.17e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC5A5—melanoma	2.02e-07	3.16e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—melanoma	2e-07	3.13e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PPARG—melanoma	1.99e-07	3.13e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—melanoma	1.99e-07	3.13e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK3—melanoma	1.98e-07	3.11e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—AKT1—melanoma	1.97e-07	3.09e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—melanoma	1.97e-07	3.09e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—melanoma	1.97e-07	3.09e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—melanoma	1.96e-07	3.08e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—melanoma	1.95e-07	3.06e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—AKT1—melanoma	1.95e-07	3.06e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CD44—melanoma	1.95e-07	3.06e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNAQ—melanoma	1.95e-07	3.06e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—melanoma	1.93e-07	3.03e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—melanoma	1.93e-07	3.03e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK1—melanoma	1.93e-07	3.02e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—melanoma	1.93e-07	3.02e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—HRAS—melanoma	1.92e-07	3.01e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—melanoma	1.92e-07	3.01e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP9—melanoma	1.91e-07	3e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—melanoma	1.91e-07	2.99e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—melanoma	1.9e-07	2.98e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—melanoma	1.9e-07	2.98e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NFKB1—melanoma	1.89e-07	2.97e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK1—melanoma	1.89e-07	2.96e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—melanoma	1.89e-07	2.96e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1B1—melanoma	1.87e-07	2.93e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—melanoma	1.86e-07	2.92e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—melanoma	1.86e-07	2.91e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—HRAS—melanoma	1.85e-07	2.9e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL6—melanoma	1.84e-07	2.88e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PRKCA—melanoma	1.84e-07	2.88e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—melanoma	1.83e-07	2.87e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—melanoma	1.82e-07	2.86e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ERCC2—melanoma	1.82e-07	2.85e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CD—melanoma	1.82e-07	2.85e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—HRAS—melanoma	1.82e-07	2.85e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—melanoma	1.8e-07	2.82e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CG—melanoma	1.8e-07	2.82e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—melanoma	1.8e-07	2.82e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ALB—melanoma	1.79e-07	2.81e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—melanoma	1.78e-07	2.8e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—HRAS—melanoma	1.77e-07	2.78e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL6—melanoma	1.77e-07	2.77e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PPARG—melanoma	1.74e-07	2.72e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL6—melanoma	1.74e-07	2.72e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—HRAS—melanoma	1.72e-07	2.7e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—melanoma	1.72e-07	2.7e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—HRAS—melanoma	1.72e-07	2.69e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STAT3—melanoma	1.7e-07	2.67e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NRAS—melanoma	1.7e-07	2.66e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—IL6—melanoma	1.7e-07	2.66e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CG—melanoma	1.7e-07	2.66e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—AKT1—melanoma	1.7e-07	2.66e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—melanoma	1.68e-07	2.63e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	1.67e-07	2.62e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL6—melanoma	1.65e-07	2.59e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL6—melanoma	1.64e-07	2.58e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—melanoma	1.64e-07	2.57e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PPARG—melanoma	1.64e-07	2.57e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—AKT1—melanoma	1.63e-07	2.56e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK3—melanoma	1.63e-07	2.55e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—melanoma	1.62e-07	2.54e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—AKT1—melanoma	1.6e-07	2.51e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—melanoma	1.58e-07	2.48e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CB—melanoma	1.58e-07	2.48e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CD—melanoma	1.58e-07	2.48e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—melanoma	1.58e-07	2.48e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—melanoma	1.57e-07	2.46e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—AKT1—melanoma	1.57e-07	2.46e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ALB—melanoma	1.56e-07	2.45e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—melanoma	1.56e-07	2.44e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—HRAS—melanoma	1.55e-07	2.43e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK1—melanoma	1.55e-07	2.43e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—melanoma	1.55e-07	2.43e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—melanoma	1.54e-07	2.41e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—AKT1—melanoma	1.52e-07	2.39e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—AKT1—melanoma	1.52e-07	2.38e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—HRAS—melanoma	1.52e-07	2.38e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.51e-07	2.36e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—AKT1—melanoma	1.5e-07	2.35e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CD—melanoma	1.49e-07	2.34e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL6—melanoma	1.48e-07	2.32e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ALB—melanoma	1.47e-07	2.31e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—melanoma	1.46e-07	2.29e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL6—melanoma	1.45e-07	2.27e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CG—melanoma	1.44e-07	2.25e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PRKCA—melanoma	1.42e-07	2.22e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ERCC2—melanoma	1.4e-07	2.2e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PPARG—melanoma	1.39e-07	2.18e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CB—melanoma	1.38e-07	2.16e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—AKT1—melanoma	1.37e-07	2.15e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—melanoma	1.37e-07	2.15e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—melanoma	1.37e-07	2.14e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—AKT1—melanoma	1.37e-07	2.14e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—melanoma	1.34e-07	2.11e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—AKT1—melanoma	1.34e-07	2.1e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CB—melanoma	1.3e-07	2.04e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—melanoma	1.3e-07	2.04e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—melanoma	1.29e-07	2.02e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—AKT1—melanoma	1.27e-07	1.99e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CD—melanoma	1.26e-07	1.98e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALB—melanoma	1.25e-07	1.96e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HRAS—melanoma	1.24e-07	1.95e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—melanoma	1.19e-07	1.87e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL6—melanoma	1.19e-07	1.86e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—melanoma	1.12e-07	1.76e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CG—melanoma	1.11e-07	1.74e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CB—melanoma	1.1e-07	1.73e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—AKT1—melanoma	1.1e-07	1.72e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—melanoma	1.09e-07	1.71e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PPARG—melanoma	1.07e-07	1.68e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CD—melanoma	9.75e-08	1.53e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—melanoma	9.66e-08	1.51e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALB—melanoma	9.63e-08	1.51e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—melanoma	9.52e-08	1.49e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CB—melanoma	8.5e-08	1.33e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—melanoma	8.42e-08	1.32e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—melanoma	8.41e-08	1.32e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—melanoma	7.93e-08	1.24e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—AKT1—melanoma	7.89e-08	1.24e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—melanoma	7.35e-08	1.15e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—AKT1—melanoma	6.87e-08	1.08e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—melanoma	6.72e-08	1.05e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—AKT1—melanoma	6.48e-08	1.02e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—AKT1—melanoma	5.49e-08	8.6e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—melanoma	5.18e-08	8.13e-07	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—AKT1—melanoma	4.23e-08	6.64e-07	CbGpPWpGaD
